The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing to raise ?2.9 million

26 Feb 2010 07:00

RNS Number : 7099H
ViaLogy PLC
26 February 2010
 



ViaLogy PLC ("ViaLogy")

Placing to raise £2.9 million 

 

London, February 25, 2010. ViaLogy (LSE:VIY) is pleased to announce that it has today raised approximately £2.88 million (gross) through the placing of 59,118,858 new ordinary shares of 1p each ("Placing Shares") at a price of 4.875p per share with certain existing shareholders ("the Placing").

The net proceeds of the Placing will be used in the further expansion of ViaLogy's Energy business which uses its proprietary QuantumRD™ technology to interpret seismic data for the location and analysis of oil well sites, as well as for general working capital purposes. 

Application has been made for the 59,118,858 Placing Shares to be admitted to trading on AIM and dealings are expected to commence on March 2, 2010. Following the Placing, the total number of ordinary shares in issue and therefore the total number of voting rights is 690,475,334

Terry Bond, chairman of ViaLogy commented: "The continuing success of ViaLogy's QuantumRD technology, and its ability to accurately predict the correct locations for well drillings in order to maximise the commercial potential of oil and gas deposits, is causing considerable interest in the O&G industry globally.

"To date we have concentrated our activities in Texas, where there are significant oil deposits in a wide variety of formations and at varying depths. In a state where the strike rate averages around 40% our first five analyses have all been successful. Our achievement is being recognised by exploration companies around the world and the additional funding will be used in part to expand ViaLogy's ability to handle the increased demand for its services."

The Company is recruiting additional geophysicists and mathematicians and acquiring additional sophisticated computer equipment. 

 

For further information please contact:

ViaLogy PLC 

 

 

 

 

 

Robert W Dean, President & CEO

 

US +1 626 296 6337

 

 

(mobile: +1 703 589 3807)

 

 

 

Terry Bond, Chairman - UK & Europe

 

+44 (0) 1235 834734

 

 

(mobile: 07860 842 756) 

 

 

 

Seymour Pierce Limited

Nominated Advisor and Broker to ViaLogy

 

 

 

 

 

Mark Percy / Catherine Leftley

 

+44 (0) 207 107 8000

 

 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOETAMFTMBITBRM
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.